Zepp Health to Showcase Groundbreaking Innovations at CES Pepcom & ShowStoppers Media Events
CES -- Zepp Health Corporation (NYSE: ZEPP), a global leader in health technology and smart wearables, is thrilled to announce its participation in the CES Pepcom and ShowStoppers media events. These exclusive platforms will unveil Zepp Health's latest smart wearables and health technology advancements, designed to empower individuals to lead healthier, more balanced lives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250106641263/en/
(Graphic: Business Wire)
Zepp Health is on a mission to empower people with intelligent healthcare tools that help them take charge of their well-being. Its innovative products integrate fitness, nutrition, health, productivity, and overall wellness to meet the demands of modern lifestyles. With millions of users in over 90 countries, Zepp Health combines advanced technology and a robust ecosystem to enhance its fitness and wellness brand, Amazfit, and its hearing solutions brand, Zepp Clarity.
From monitoring fitness and sleep to providing nutrition insights through Amazfit, and advanced hearing solutions with Zepp Clarity, Zepp Health supports every step of life’s journey, helping individuals achieve balance and fulfillment. Future innovations, like seamless connectivity between Zepp Clarity hearing aids and Amazfit smartwatches via Zepp OS, will deliver unparalleled integration for a holistic wellness experience.
What Zepp Health Will Showcase
1. Amazfit Active 2 Smartwatch Series: The Everyday Smartwatch -The perfect companion for fitness enthusiasts and multitaskers, this series offers:
- Zepp Coach™: AI-driven personalized fitness plans tailored to individual goals.
- Zepp Flow™: A powerful voice assistant for effortless interaction and control.
- Over 160+ sports modes, extended battery life, and premium design options for every lifestyle.
2. Amazfit V1TAL Prototype: Your Personal Nutritionist and Lifestyle Companion -Revolutionizing dietary management and lifestyle enhancement, the Amazfit V1TAL (pronounced "Amaz-fit Vee-TAL") features:
- Advanced Nutritional Tracking: Real-time meal analysis via automated sensors and personalized dietary recommendations.
- High-Definition Video Capture: Wearable or desk-mounted for recording life’s special moments.
- AI-Powered Assistant: Enhances productivity and wellness while keeping users connected.
- Zepp Ecosystem Integration: Syncs seamlessly with the Zepp App for holistic fitness, sleep, and nutrition tracking.
When launched, the V1TAL will integrate with the Zepp App's Food Log feature, enabling real-time meal analysis with a simple photo and providing personalized nutritional insights.
3. Revamped Zepp App -The revamped Zepp App 9 now includes:
- Zepp Coach™: Intelligent fitness tracking and recovery recommendations.
- Zepp Aura: AI-driven sleep tracking and personalized wellness reports.
- Food Log: Instant meal analysis for nutritional insights, complementing Amazfit V1TAL's features.
4. Health Solutions for Women Powered by Wild.AI -In collaboration with Wild.AI, Amazfit Active devices now offer:
- Tailored health and fitness insights for women’s unique hormonal cycles.
- Personalized recovery and fitness recommendations, addressing the gender gap in health technology.
5. Zepp Clarity Pixie: Nearly Invisible Hearing Aids -Addressing the global hearing loss epidemic, Zepp Clarity Pixie delivers:
- Pitch-perfect sound clarity for superior hearing experiences.
- A sleek, nearly invisible design for comfort and confidence.
- Features to keep users connected and improve quality of life.
Event Details
Experience these innovations firsthand:
- Pepcom: January 6th, 6–10 PM, Caesars Palace.
- CES ShowStoppers: January 7th, 6–10 PM, Bellagio.
These events provide media professionals with the opportunity to explore Zepp Health’s integrated solutions for fitness, sleep, nutrition, hearing, and productivity, creating a comprehensive wellness ecosystem.
Why Zepp Health?
Zepp Health addresses critical global health challenges:
- 1.4 billion adults at risk of chronic diseases due to physical inactivity.
- 62% of adults experience inadequate sleep.
- 2.5 billion people are projected to suffer hearing loss by 2050.
Inspired by its tagline, "Empowering Health, Inspiring Joy," Zepp Health continues to create wellness solutions that are accessible, personalized, and transformative.
About Zepp Health
Zepp Health (NYSE: ZEPP), a global smart wearable and health technology leader, empowers users to live their healthiest lives by optimizing their health, fitness, and wellness journeys through its leading consumer brands, Amazfit, Zepp Clarity, and Zepp Aura. Powered by its proprietary Zepp Digital Health Management Platform, which includes the Zepp OS, AI chips, biometric sensors, and data algorithms, it delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. To date, Zepp Health has shipped over 200 million units and its products are available in 90+ countries. Founded in 2013, Zepp Health has 1000+ employees and offices across the Americas, EMEA, and APAC regions. For more information, visit www.zepp.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106641263/en/
Contacts
Tanita Sandhu
tanita.sandhu@zepp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 20258.1.2025 08:00:00 CET | Press Release
Azafaros B.V. today announced that its lead asset, nizubaglustat, has been granted orphan drug designation from regulatory authorities in both the United States and the European Union for the treatment of GM1 gangliosidosis. Additionally, the company’s Clinical Trial Application (CTA) for two global Phase 3 studies investigating the drug’s efficacy and safety in GM1/GM2 gangliosidoses and Niemann-Pick Type C (NPC) was approved by multiple European countries. Azafaros expects to initiate the two global trials in Q2, 2025. The company’s lead product is a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1/GM2 gangliosidoses and NPC. Positive topline data reported earlier this year from the company’s successful Phase 2 study investigating nizubaglustat in GM2 and NPC patients demonstrated that the compound had a positive safety profile. Preliminary improvements or the stabilization of clinical endpoints were observed in the majority of pat
AWS Launches Infrastructure Region in Thailand8.1.2025 03:00:00 CET | Press Release
Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today announced the launch of the AWS Asia Pacific (Thailand) Region. Now, developers, startups, entrepreneurs, and enterprises, as well as government, education, and nonprofit organizations, will have greater choice for running their applications and serving end users from AWS data centers located in Thailand. As part of its long-term commitment, AWS is planning to invest more than $5 billion in Thailand. For more information about AWS Global Infrastructure, visit aws.amazon.com/about-aws/global-infrastructure. AWS estimates the construction and ongoing operation of the new AWS Region will add approximately $10 billion to Thailand’s gross domestic product (GDP) and support an average of more than 11,000 full-time-equivalent jobs at external businesses annually. These jobs, including construction, facility maintenance, engineering, telecommunications, and others within the country’s broader economy, will be pa
The Apollo Group Partners with Oaktree Capital to Facilitate its Next Phase of Growth7.1.2025 23:01:00 CET | Press Release
The Apollo Group (“Apollo” or the “Company”), the leading provider of full-service hospitality management services to the cruise industry, has announced a transformative growth investment from funds managed by Oaktree Capital Management, L.P. ("Oaktree"). Apollo specializes in essential and turnkey hospitality services including crew management, food services, food and beverage distribution, end-to-end procurement and logistics and other related services. This investment will enable Apollo to continue to provide best in class service to its existing customer base while expanding its capabilities in food and beverage distribution. "As we explored potential investment partners, Oaktree stood out because of its hands on approach and storied history of successful investing in F&B and hospitality management companies," said Jose Ramon Barrera, CEO of Apollo. “Oaktree’s significant capital resources and experience in hospitality management will be critical to achieving Apollo’s strategic gro
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors7.1.2025 23:00:00 CET | Press Release
Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250107874851/en/ Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors. (Graphic: Business Wire) This collaboration combines Biocytogen’s RenLite® platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology to tackle some of the toughest challenges in oncology—tumor heterogeneity and drug resistance. This novel approach aims to address these complexities by utilizing dual-payloads that target multiple therapeutic or disease pathways. These payloads are delivered with bispecific antibodies that enable enhanced precision and functionality. As part of the strategic partnership, Biocytogen will provide a bispecific anti
SPIE, the International Society for Optics and Photonics, Announces Its 2025 Fellows7.1.2025 22:49:00 CET | Press Release
This year, SPIE, the international society for optics and photonics, welcomes 47 Members as new Fellows of the Society. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250107849416/en/ SPIE, the international society for optics and photonics, welcomes 47 new Fellows in 2025. (Graphic: Business Wire) The inductees this year represent high-profile leaders in academia, industry, and government, many of whom are prominent in their support of the optics and photonics community and mentorsh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom